Sign In
Last checked at 
11 May 2020 16:10
Non-Executive Director appointment
Reading, United Kingdom (11 May 2020)
ConvaTec Group Plc ("ConvaTec" or "the Company") announces the appointment of Heather Mason as a Non-Executive Director of the Company with effect from 1 July 2020.
Heather has significant international healthcare experience leading fully integrated global businesses. Previously she spent 27 years with Abbott Laboratories where she held a number of global senior operational and strategic leadership roles, including Senior Vice President of Abbott Diabetes Care and most recently Executive Vice President of Abbot Nutrition. She retired from Abbot Laboratories in 2017.
John McAdam, Chairman of ConvaTec, commented:
"I am very pleased to welcome Heather to our Board. She has deep healthcare knowledge and brings very relevant international, commercial and operational experience. In particular, as we increase our focus on innovation to help drive our transformation, her track record of overseeing the development of commercially viable new product pipelines and brand building will be invaluable."
Heather is currently a Non-Executive Director of Assertio Therapeutics, Inc., the Nasdaq listed specialty pharmaceutical company focused on providing responsible solutions to advance patient care in the areas of neurology, orphan and speciality medicines. She is also Co-Chair of the University of Michigan's College of Engineering Innovation Committee and a member of its Leadership Advisory Board.
No other information requires disclosure in accordance with Listing Rule 9.6.13.
This announcement is made in accordance with Listing Rule 9.6.11R(1).
Enquiries:
Analysts and Investors
Mark Reynolds, Director Investor Relations +44 (0)7551 036 625
ir@convatec.com
Media
Buchanan: Charles Ryland/Chris Lane/Vicky Hayns +44 (0)207 466 5000
About ConvaTec
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions. The Company is listed on the London Stock Exchange (stock symbol: CTEC) and has established market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. ConvaTec's products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. www.convatecgroup.com.
Follow the stocks
